this morning from broker GS,
We revise our FY20E/FY21E/FY22E NPAT forecasts by
+21%/+19%/+8% to factor in CCX’s trading update and equity
raising, but not the potential acquisition of Catherines. CCX’s clear
intent to make strategic investments with this capital sees us
increase our target multiples to CCX’s forward earnings, detailed
inside. Our revised 12-month target price of A$4.15 (previously
A$3.20) provides potential 19% upside. Retain our Buy rating
Ann: Appendix 3Y - Change of Director's Interest Notice, page-2
Add to My Watchlist
What is My Watchlist?
